Humanoid Robot Concept Stocks Watch | Xiaomi-W (01810.HK) Fluctuates Down Over 3%, Robotics Division Recently Releases Embodied Foundation Model
NewTimeSpace (newtimespace.com) reported that on July 17, 2026, the humanoid robot theme weakened significantly, with Xiaomi-W (01810.HK) fluctuating lower. As of 13:13, the stock was quoted at HKD 26.660, down 3.05%.
On the news front, Xiaomi's robotics division recently released Xiaomi-Robotics-1, an embodied foundation model designed for real‑world mobile manipulation tasks. The model is pre‑trained on 100,000 hours of real‑world data and further post‑trained with cross‑embodiment data. After post‑training, Xiaomi-Robotics-1 is capable of directly executing a wide range of mobile manipulation tasks in real‑world environments based on natural language instructions.
Bohai Securities stated that continued breakthroughs in AI technology are accelerating the transition of the humanoid robot industry from R&D to large‑scale manufacturing. The Ministry of Industry and Information Technology recently indicated that China's humanoid robot production volume is expected to exceed 100,000 units in 2026. On the policy front, intelligent robots have also been included in the initiative to expand digital consumption, and the development of new scenarios and business models will further unleash demand potential.
XIAOMI-W (01810.HK) Leverages its massive AIoT ecosystem network and full-stack proprietary AI algorithms to advance the collaborative deployment of consumer- and industrial-grade embodied AI devices. Algorithms for its CyberOne humanoid robot and CyberDog bionic quadruped robot undergo continuous iteration. The underlying multi-modal machine vision, force-control algorithms, and automated scheduling logic are deeply integrated into the "dark factory" operations and flexible manufacturing workflows of Xiaomi's smart factories, establishing a complete closed-loop model of "algorithm + hardware + proprietary manufacturing application scenarios."
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SKB BIO (06990.HK): ESMO Data for Sac-TMT in Two Phase III Lung Cancer Studies
- QUANTGROUP (02685.HK): Unit to Supply Up to 2,000 AI Robots by End-2027 Under Framework Deal
- CSTONE PHARMA-B (02616.HK): CS2009 Data in 300+ Patients at ESMO; 100% ORR in 1L NSCLC Cohort
- LEADS BIOLABS-B (09887.HK): Updated LBL-034 Data in RRMM Presented at ESMO
- MICROINTELLIGENCE (03275.HK): Delays Global Offering and Listing; Application Monies to Be Refunded